DOI:
10.1055/s-00035026
Applied Clinical Informatics
LinksClose Window
References
Ali AK.
Pharmacovigilance analysis of adverse event reports for aliskiren hemifumarate, a first-in-class direct renin inhibitor.
Ther Clin Risk Manag 2011;
7: 337-344.
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.